Radioligand therapy, in depth.
-
Alpha vs Beta Emitters: How Isotope Choice Changes Radioligand Target Selection
Actinium-225 and lutetium-177 reward different targets. How path length, LET, daughter recoil and vector half-life change what makes a good radioligand target.
-
Radioligand Targets for PSMA-Low and PSMA-Negative Prostate Cancer
Which targets can carry a radioligand when PSMA can't? STEAP1, KLK2, CD46, B7-H3, GRPR, DLL3 and FAP compared for PSMA-low and PSMA-negative prostate cancer.
-
Radioligand Target Due Diligence: A 12-Point Checklist for BD and Investment Teams
Evaluating a radioligand asset or target? A 12-point due diligence checklist covering localization, dosimetry risk, internalization, shedding, isotope fit, precedent and competition.
-
Beyond PSMA: Emerging Radioligand Therapy Targets in Solid Tumors
A maintained landscape of next-generation radioligand therapy targets beyond PSMA and SSTR2 — DLL3, FAP, GRPR, Nectin-4, CXCR4, STEAP1 and more, with clinical stage and expression profiles.
-
Reading Normal-Tissue Expression for Radioligand Dosimetry Risk
How normal-tissue RNA and protein expression in kidney, liver, marrow and salivary glands maps to dose-limiting organ risk in radioligand therapy — and where it stops being predictive.
-
What Makes a Good Radioligand Therapy Target? A 6-Criteria Framework
The six properties that decide whether a protein can become a radioligand therapy — cell-surface access, normal-tissue safety, tumor specificity, internalization, clinical maturity, and competition.